Nine people in Valancherry, Malappuram, tested positive for HIV from contaminated needles. The local health department ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was honored with the "Best CDMO in Automated Aseptic Filling" award at the Taiwan Biopharma Excellence ...
Track Caplin Point Laboratories share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback